At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 302 enrolled
Drug / intervention
PF-06372865 +2 moredrug
Likely dose
Naproxen 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo- And Active-controlled, 4 Week, Multi-center, Parallel Group Study Assessing The Analgesic Effect, Safety And Tolerability Of Pf-06372865 In Subjects With Chronic Low Back Pain Using Naproxen As Positive Control
In Brief
A Phase 2 clinical trial evaluating PF-06372865, Placebo, and 1 other intervention for Chronic Low Back Pain. Completed, enrolled 302 participants across 46 sites.
Detailed Summary
PF-06372865 In Subjects With Chronic Low Back Pain
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Low Back Pain
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedOct 2014
Primary CompletionAug 2015
TodayJul 2026
First PostedOct 13, 2014
Enrollment StartOct 1, 2014
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.7 years ago
Interventions
PF-06372865drug
Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
Placebodrug
Placebo for PF-06372865 and placebo for naproxen daily
Naproxendrug
500 mg BID for 4 weeks